BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Robles-Jara C, Robles-Medranda C, Moncayo M, Landivar B, Parrales J. Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity? World J Gastroenterol 2008; 14(18): 2838-2843 [PMID: 18473407 DOI: 10.3748/wjg.14.2838]
URL: https://www.wjgnet.com/1007-9327/full/v14/i18/2838.htm
Number Citing Articles
1
John E. Lopes. Helicobacter pylori infection: Update on diagnosis and managementJournal of the American Academy of Physician Assistants 2010; 23(7): 20 doi: 10.1097/01720610-201007000-00005
2
Yuhong Yuan, Alex C Ford, Khurram J Khan, Javier P Gisbert, David Forman, Grigorios I Leontiadis, Frances Tse, Xavier Calvet, Carlo Fallone, Lori Fischbach, Giuseppina Oderda, Franco Bazzoli, Paul Moayyedi. Optimum duration of regimens forHelicobacter pylorieradicationCochrane Database of Systematic Reviews 2013;  doi: 10.1002/14651858.CD008337.pub2
3
F. Sierra, J.D. Forero, M. Rey. Tratamiento ideal del Helicobacter pylori: una revisión sistemáticaRevista de Gastroenterología de México 2014; 79(1): 28 doi: 10.1016/j.rgmx.2013.03.003
4
F. Sierra, J.D. Forero, M. Rey. Ideal treatment for Helicobacter pylori: A systematic reviewRevista de Gastroenterología de México (English Edition) 2014; 79(1): 28 doi: 10.1016/j.rgmxen.2014.05.001
5
H. HIRAISHI, K. HARUMA, H. MIWA, H. GOTO. Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection – the results of a multicentre, double‐blind, randomized clinical trial (IMPACT study)Alimentary Pharmacology & Therapeutics 2010; 31(8): 824 doi: 10.1111/j.1365-2036.2010.04250.x